Dr. Cheng Yuanxiong

Dr. Cheng Yuanxiong is a distinguished respiratory specialist and academic leader with over 36 years of clinical and research excellence. As current Director of Respiratory and Critical Care Medicine at Southern Medical University’s Third AƯiliated Hospital—and former Deputy Director at Nanfang Hospital—he combines clinical practice with groundbreaking research. He was trained by top specialist round the world such as Professor Zhong Nanshan (Academician, Chinese Academy of Engineering) during his doctoral studies, and Dean Metcalf (President, American Asthma and Allergy Society) during his U.S. postdoctoral fellowship.

Specializing in complex respiratory and critical care medicine, Dr. Cheng excels in:

1. Diagnosis/treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), chronic cough, severe pneumonia, and lung tumors.
2. Advanced bronchoscopy techniques, including minimally invasive tumor therapy, medical thoracoscopy, and airway stenosis management (ranked at China’s highest technical tier).
3. Critical care rescue and rapid pathogen detection via ROSE+ technology and respiratory nucleic acid testing. His leadership has established pioneering protocols for interventional lung disease and respiratory infections.

Trained as a Visiting Scholar at Northwestern University (USA) and holding a Doctorate in Medicine from Jinan University, Dr. Dong bridges clinical practice with rigorous research. His focus spans:

• Refining minimally invasive techniques for metabolic disorders.
• Advancing evidence-based protocols for gastrointestinal cancer surgery.
• Optimizing hernia repair durability through anatomical precision. He actively translates research into practice as a Reviewer for Obesity Surgery, Young Editorial Board Member of the Chinese Journal of General Surgery, and Secretary General of the Obesity and Metabolic Surgery Committee (Guangdong Medical Association).

1. Immunology of Airway Diseases: Seminal research on monocyte roles in IgE- mediated allergic regulation (internationally recognized).
2. Gene Therapy Frontiers: Current projects include gene-editing cell immunotherapy for lung cancer, bronchial ciliary dysfunction, and antitrypsin deficiency.

An influential voice in respiratory medicine, Dr. Cheng chairs/co-leads 15+ committees, including:

• Chairman, Respiratory Disease Committee (Guangdong Clinical Medicine Association).
• Vice Chairman, Methylation Marker Expert Committee (Chinese Anti-Cancer Association).
• Standing Member, Pan-Greater Bay Area Respiratory Oncology Alliance. His former roles include Vice President of the NIH-aƯiliated Chinese Immunology Association and membership in the American Academy of Allergy, Asthma, and Immunology (AAAAI)